Key statistics
As of last trade, Ultragenyx Pharmaceutical Inc (UP0:FRA) traded at 19.90, 18.45% above the 52 week low of 16.80 set on Dec 30, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 19.90 |
|---|---|
| High | 19.90 |
| Low | 19.90 |
| Bid | 19.90 |
| Offer | 20.20 |
| Previous close | 21.00 |
| Average volume | 220.56 |
|---|---|
| Shares outstanding | 96.48m |
| Free float | 93.45m |
| P/E (TTM) | -- |
| Market cap | 2.30bn USD |
| EPS (TTM) | -5.94 USD |
Data delayed at least 15 minutes, as of Feb 10 2026 07:00 GMT.
More ▼
- Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update
- Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)
- Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
- Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
- Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx to Participate in Investor Conferences in December
More ▼
